Chordia Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Chordia Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-6.9%

Buyback Yield

Total Shareholder Yield	-6.9%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

We're Hopeful That Chordia Therapeutics (TSE:190A) Will Use Its Cash Wisely

Dec 19

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if 190A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 190A's dividend payments have been increasing.

Dividend Yield vs Market

Chordia Therapeutics Dividend Yield vs Market

How does 190A dividend yield compare to the market?
Segment	Dividend Yield
Company (190A)	n/a
Market Bottom 25% (JP)	1.8%
Market Top 25% (JP)	3.8%
Industry Average (Biotechs)	1.1%
Analyst forecast (190A) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate 190A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 190A's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate 190A's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 190A has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 18:30
End of Day Share Price	2024/12/27 00:00
Earnings	2024/08/31
Annual Earnings	2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chordia Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution